Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
By Elana Gotkine HealthDay Reporter
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes, according to a study published online May 24 in the New England Journal of Medicine to coincide with the annual European Renal Association Congress, held from May 23 to 26 in Stockholm.
Vlado Perkovic, M.B., B.S., Ph.D., from the University of New South Wales in Sydney, and colleagues randomly assigned patients with type 2 diabetes and chronic kidney disease to receive subcutaneous semaglutide (1.0 mg weekly) or placebo (1,767 and 1,766 participants, respectively).
Participants were followed for a median of 3.4 years after recommendation of early trial cessation at a prespecified interim analysis. The researchers found that the risk for a primary outcome event (major kidney disease events, a composite of the onset of kidney failure, at least a 50 percent reduction in the estimated glomerular filtration rate from baseline, or death from kidney-related or cardiovascular causes) was significantly lower in the semaglutide group (331 versus 410 first events; hazard ratio, 0.76). Similar results were seen for a composite of the kidney-specific components of the primary outcome and for death from cardiovascular causes (hazard ratios, 0.79 and 0.71, respectively). All confirmatory secondary outcomes favored semaglutide.
"These benefits reflect important clinical effects on kidney, cardiovascular, and survival outcomes among high-risk patients, particularly given the reassuring safety findings, and support a therapeutic role for semaglutide in this population," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mortality, Sudden Cardiac Death Higher for Male Professional Bodybuilders
THURSDAY, May 22, 2025 -- The risks for death and sudden cardiac death (SCD) are higher for male bodybuilders than amateurs, according to a study published online May 20 in the...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Poor Cardiovascular Outcomes Up in Aging Patients With Down Syndrome
THURSDAY, May 15, 2025 -- Individuals with Down syndrome are at increased risk of poor cardiovascular outcomes, according to a study published online May 7 in the Journal of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.